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Abstract
We present a new antiviral strategy and research tool that could be applied to a wide range of enveloped viruses that infect
human beings via membrane fusion. We test this strategy on two emerging zoonotic henipaviruses that cause fatal
encephalitis in humans, Nipah (NiV) and Hendra (HeV) viruses. In the new approach, artificial cell-like particles (protocells)
presenting membrane receptors in a biomimetic manner were developed and found to attract and inactivate henipavirus
envelope glycoprotein pseudovirus particles, preventing infection. The protocells do not accumulate virus during the
inactivation process. The use of protocells that interact with, but do not accumulate, viruses may provide significant
advantages over current antiviral drugs, and this general approach may have wide potential for antiviral development.
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Introduction
Nipah (NiV) and Hendra (HeV) viruses are emerging zoonotic
paramyxoviruses of the henipavirus family that cause fatal
encephalitis in humans, with fatality rates of up to 75% [1–3].
Emerging zoonotic viruses are recently identified agents that can
be transmitted from animals to humans and person-to-person;
they often spread widely through animal hosts before infecting
humans. Paramyxoviruses are single stranded RNA viruses that
include a number of human pathogens. Henipaviruses share
common structures such as a lipid envelope, receptor binding
proteins (referred to as ‘‘G’’) and fusion proteins (referred to as
‘‘F’’). Direct transmission of NiV from its fruit bat (flying fox)
mammalian reservoir to humans, and person-to-person transmis-
sion, allows infection to bypass the pig host which served to
transmit the virus as it emerged into the human population[4].
HeV, also via a bat host, has caused disease in horses with
transmission to horse-handlers and veterinarians, and since 1995
has caused sporadic illness in Australia [5]. NiV, in addition to
acute infection, may cause asymptomatic infection in up to 60% of
exposed people, and may lead to late-onset disease or relapse of
encephalitis years after initial infection [6]. The vast geographic
range of the fruit bat mammalian reservoir raises the possibility of
wide spread of these human diseases, which presently have no
approved clinical treatment or vaccine [7]. Other related human
pathogens in the paramyxovirus family include parainfluenza
viruses, respiratory syncytial virus (RSV), mumps and measles, all
causes of significant human diseases affecting millions of children
yearly.
The first steps in infection with paramyxoviruses are binding to
the target cells, via interaction of the viral receptor-binding
molecule (G for HeV or NiV) with the specific receptor molecules
on the cell surface –EFNB2 (Ephrin-B2) for HeV, and both
EFNB2 and EFNB3 for NiV, followed by the fusion of the viral
envelope with the plasma membrane of the cell, a process
mediated by the viral fusion protein (F). The receptor binding
protein G, when engaged with receptor, ‘‘triggers’’ F to assume its
fusion-ready conformation with its fusion domain exposed [8].
While F-activation is key for entry, the correct timing is critical.
We suggest[9] that this timing of activation represents a target for
intervention with infection, and that with the correct receptor
mimic presented in the proper biological context, it is possible to
induce triggering and to inactivate F, rendering the virus
noninfectious.
Artificial cell-like particles, or protocells, bearing receptor
mimics to attract and inactivate henipavirus envelope glycoprotein
pseudotypes offer a new approach to preventing infection. To
assess this strategy, we used quantitative assays for inhibitors of
henipavirus infection that are based on envelope glycoprotein
pseudotypes [10]. The pseudotypes bear the henipavirus entry
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use the identical entry mechanism as live henipaviruses[10].
Agents found to be inhibitory in this assay may either be those that
block binding, or interfere with processing of F, or interfere with F
activation and fusion. This strategy was used here to assess the
inhibitory potential of this novel approach to anti-infectives: to
determine whether synthetic protocells that bear the entry
receptor for henipaviruses inactivate pseudotyped viruses.
Development of artificial cells presenting membrane
bound receptors (‘‘protocells’’)
Protocells have great potential to fight human disease [11] and
serve as a platform to apply nanobiotechnology to treat disease
[12,13]. The protocells described here allow for biomimetic
presentation of surface receptors in lipid bilayers that are
supported on highly hydrophilic nanoporous silica particles. The
construction of the protocells bearing henipavirus entry receptors
is diagrammed in figure 1. Test protocells were prepared (shown in
figure 1a) using 3 mm diameter nanoporous SiO2 particles
following the methods of Brinker et al [14,15]. Previous work
has shown that lipid bilayers can be conveniently assembled over
nanoporous silica surfaces and support the lipid bilayer in a fluid
state analogous to the lipid bilayer supported on the actin
cytoskeleton; nanoporous silica particles were selected to form the
cell-like particles [16,17] (Movie S1 shows confocal results of cell-
like particles bearing EFNB2 in a red-fluorescent labeled lipid
bilayer binding to the surface of engineered 3T3 cells presenting G
and F; one of several control studies performed to confirm
protocell synthesis). Nanoporous silica is viewed as biocompatible
as silica is a micronutrient that will be absorbed in the body, forms
of silica are used in food preparation and have been utilized for
drug delivery [18]. It should be noted these particles are not
crystalline silica – crystalline silica is associated with the
occupational lung disease silicosis. A nickel chelating lipid bilayer
was formed on the surface of the particles[19,20]. Polyhistidine-
tagged EFNB2 or EFNB1 (negative control; not a viral receptor)
was then attached to the Ni2+ sites present in the lipid. Aliquots of
purified soluble HeV G were incubated with the protocells; the
presence of HeV G bound to the protocells was assessed by
fluorescent microscopy and flow cytometry as shown in figure 1b.
The protocells bearing EFNB2 efficiently bound HeV G and were
fluorescent, while the protocells bearing EFNB1 did not bind HeV
G, as expected.
Protocells inactivate pseudotyped viruses
Protocells were incubated with pseudotyped viruses for one
hour at 37uC and then the viral titer (as determined by viral entry
on cultured human cells) was assessed and compared to the titer of
untreated pseudotyped viruses. Individual protocells contained
either EFNB1, EFNB2 or mixtures of the two; EFNB2 presenting
protocells effectively inhibited entry by HeV pseudotyped virions,
causing a dramatic decrease in viral titer after incubation with the
protocells. The inhibitory effect of the protocells is specific for
henipaviruses. Incubation with paramyxovirus human parainflu-
enza virus type 3, and with the rhabdovirus VSV, each of which
uses a different entry receptor, did not result in a significant
decrease in titer. In these experiments, pseudovirus infection was
reduced 100% using the EFNB2 bearing protocells but VSV
infection was reduced 11% when exposed to EFNB2 protocells
(relative standard deviation is 13% for these measurements),
confirming the specificity of inhibition.
The inhibitory activity of EFNB2-bearing protocells is temper-
ature dependent; infection of cultured cells is specifically inhibited
after incubation at 37uC but not at 4uC (figure 2). In these
experiments, pseudotyped viruses (hereafter called pseudovirus)
were incubated with EFNB2 or EFNB1-bearing protocells at 4uC
or 37uC, and then introduced to a culture with mammalian cells.
In parallel, pseudoviruses were incubated with EFNB2-bearing
sepharose beads at 4uCo r3 7 uC. The sepharose beads provide an
example of a presentation of receptor molecules in a static, non-
biomimetic fashion, for comparison. Flow cytometry was carried
out to determine the percentage of infected cells based on the
expression of red fluorescent protein (RFP) gene incorporated into
the pseudovirus. The cells that were infected by the pseudovirus
are fluorescent; in each panel of figure 2, the top section represents
the fluorescent cells counted in the flow cytometer. A control
experiment with mock cells was run as part of each flow cytometer
experiment to determine where the cut-off line should fall. In case
of experiments to measure soluble G binding, the cut-off indicates
fluorescent intensity indicative of binding; In the case of
experiments to measure entry, the cut-off indicates fluorescent
intensity associated with entry and expression of red fluorescent
protein. Running mock cells before each experimental batch
avoids falsely counting auto-fluorescence as a positive result. The
raw flow cytometer plots display fluorescent intensity on axis
(labeled UV1) versus an index of cell size from the side scatter
detector (labeled SSC). Each dot on the plot is a single cell from
Figure 1. Scheme to produce synthetic protocells. a: planar or spherical nanoporous SiO2 surface with a lipid bilayer and EFNB2 binding
protein. b: scheme used to confirm presence and activity of EFNB2 using purified Hendra G and primary and secondary antibodies.
doi:10.1371/journal.pone.0016874.g001
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large cell population.
In the lower right-hand panel of figure 2 (pseudovirus exposed at
37uC to EFNB2-bearing protocells before introduction of pseudo-
virus to mammalian cells) there is a drastic reduction in signal in the
top section, indicating a reduction in the number of infected cells.
For cells incubated with pseudovirus after exposure to the EFNB2-
bearing protocells at 37uC, only 2.0% of cells were infected. The
EFNB1-bearing protocells are not inhibitory and serve as negative
controls with the same silica core and lipid bilayer, but a non-
specific membrane protein. At the incubation temperature of 4uC–
a temperature at which viral fusion machinery (F) is inactive –
inactivation did not occur during the incubation with EFNB2-
bearing protocells. For cells incubated withthe pseudovirus exposed
to EFNB2-bearing protocells at 4uC, the number of infected cells
did not decrease, remaining approximately the same, at 18.2% and
16.0% (percentage of total cells exposed that became infected, for
different conditions as shown in figure 2) respectively. In contrast,
flow cytometry measurements of soluble G binding to EFNB2
bearing protocells was equal at 4uC and 37uC and soluble G did not
bind to EFNB1 containing protocells (figure 3). These results show
that inhibition by protocells occurs only at 37uC and not at 4uCa n d
is not due to non-specific interactions, and that inactivation of
infectivity by protocells, in distinction from binding to sepharose
beads, entails a temperature-dependent step.
The antiviral protocells do not accumulate virus
EFNB2-bearing protocells or, in parallel, sepharose beads
bearing EFNB2, were incubated with pseudoviruses in concen-
trations ranging from 0.5 plaque-forming units (pfu) per protocell
Figure 2. Inhibition of viral titer by protocells requires a 376C step. Flow cytometry results showing cells infected with pseudoviruses after
incubation with EFNB2 or EFNB1 bearing protocells at 4uC and 37uC. Data points falling above the line indicate that entry occurred and the cells
expressed red fluorescent protein. FL1 is the fluorescent detector data that indicates measurement of a fluorescent label; SSC is side scatter data that
indicates size. The location of the red line is determined by control experiments.
doi:10.1371/journal.pone.0016874.g002
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collected and titered for infectious pseudoviruses. For the EFNB2-
bearing protocells, activity vs. pseudoviruses was retained in our
determination range, regardless of the concentration of virus
(figure 4a) or concentration of protocells (figure 4b). To assess
whether the protocells retain activity after repeated use, the
EFNB2-bearing protocells and EFNB2-bearing sepharose beads
(in parallel with protocells bearing EFNB1 and sepharose particles
bearing anti-F antibodies) were washed, incubated with new
pseudoviruses, and re-titered (figure 5). For each repetition (I–IV)
the used protocells or particles were washed, pelleted, and
incubated with new pseudoviruses. For the EFNB2-bearing
protocells, activity vs. pseudoviruses was retained more strongly
than the sepharose beads. The red bars in figure 4 show that
EFNB2-bearing protocells retain significant inhibitory activity
even at the fourth re-incubation. In contrast, as shown by the blue
and green bars in figure 5, the efficacy of the sepharose beads
bearing EFNB2 or anti-F antibodies had no inhibitory effect
observed after the second use (t-test applied to means, each mean
based on n=3, 90% confidence intervals or higher). These data
highlight a key feature of the protocells: they are reusable. Because
of a larger number of binding sites on the sepharose beads, the
comparison shown in figure 5 was biased in their favor – the
sepharose beads contained roughly 10 times the number of ligands
per bead as the protocells, evaluated with gel electrophoresis of
EFNB2 removed from the beads and compared to lanes with
EFNB2 of known concentration. Figure S1 shows typical gel
electrophoresis results for EFNB1 and EFNB2 concentration
Figure 3. Binding of soluble Hendra G to EFNB1 and EFNB2 bearing protocells measured at 46C and 376C using flow cytometry.
These plots show that soluble HEV G binding occurs equally to EFNB2 bearing protocells at these two temperatures and that there is little (not
significant) soluble HEV G non-specific binding to the negative control protocells bearing EFNB1. FL1 is the fluorescent detector data that indicates
measurement of the fluorescent label; SSC is side scatter data that indicates size.
doi:10.1371/journal.pone.0016874.g003
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known protein concentrations.
To further assess whether inactivation is a consequence of
binding, we asked whether there is any correlation between the
surface concentration of EFNB2 on protocells and their effective-
ness. For the measurements shown in figure 6, a panel of protocells
were synthesized that bear different ratios of EFNB1 (not a
receptor) and EFNB2 (receptor for G), ranging from 100% EFNB1
(0% EFNB2) on the left, to 0% EFNB1 (100% EFNB2) on the
right. In panel (a), the protocells were incubated with pseudovirus
at 37uC, and flow cytometry performed to quantify the inhibition
of infectivity; in panel (a), the top section represents the fluorescent
Figure 4. Inhibitory activity of protocells. a: Inhibitory effect is not saturated by increasing amounts of pseudovirus over this concentration
range. Percent inhibition of viral titer by exposure to protocells bearing EFNB2, after addition of varying amounts of pseudovirus. b: Inhibitory effect is
not saturated by decreasing the number of protocells over this concentration range. (Bars are mean 6 one standard deviation, N=3).
doi:10.1371/journal.pone.0016874.g004
Figure 5. Inhibition of viral titer after repeated exposure of protocells bearing EFNB1 or EFNB2 along with sepharose particles
bearing EFNB2 and sepharose particles bearing anti-F antibodies. For each repetition (1–4) the used protocells/particles were washed,
pelleted, and re-incubated with fresh pseudovirus. The EFNB2-bearing protocells retain some inhibitory activity after four uses. * t-test for difference
in means significant at 90% or greater confidence interval. ** t-test for difference in means significant at 88% confidence interval. *** t-test for
difference in means significant at 84% confidence interval (Bars are mean 6 one standard deviation. N=3 except EFNB1-bearing protocells (negative
controls) which were pooled with N=12).
doi:10.1371/journal.pone.0016874.g005
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same protocells were incubated with aliquots of purified soluble
HeV G at 37uC (b) or at 4uC (c), and the presence of HeV G on
the protocells was quantified by flow cytometry using fluorescently
labeled antibodies. The protocells bearing the higher concentra-
tions of EFNB2 efficiently bound HeV G and were fluorescent,
while the protocells bearing the most EFNB1 did not bind HeV G,
as expected, and binding increased corresponding to increasing
ratios of EFNB2:EFNB1. Binding was equivalent at 37uC and at
4uC. Strong viral inactivation occurred with 50% EFNB2 at 37uC,
even though binding of soluble HeV G was reduced due to the
lower number of EFNB2. Likewise, little viral inactivation
occurred at 4uC (see figure 2) though binding of soluble HeV G
is equivalent at 37uC and at 4uC (panels 6b and 6c). The results
suggest that the viral inactivation that occurs upon incubation with
EFNB2-bearing protocells at 37uC, while it requires interaction
with EFNB2 receptor, is not attributable to receptor binding
alone, but requires an additional step. We propose that this step is
the inopportune activation of F.
Discussion
The antiviral protocells that we describe act specifically,
effectively and renewably to inactivate pseudovirus, and do so
only under conditions that permit triggering of the viral fusion
protein. A temperature-dependent step is required for viral
inactivation. Our hypothesis regarding the mechanism of
inhibition by these protocells is that the protocells work as decoys;
the virus interacts with the EFNB2 in the fluid surface of the
particles, and then the F protein is triggered, rendering the virus
inactivated. This hypothesis is supported by a number of
observations: First, no virus particles or viral proteins have been
Figure 6. Inactivation of virus by protocells with mixtures of viral receptors and non-specific membrane proteins does not correlate
with binding to soluble HeV G. a: inhibition of the infectivity of pseudoviruses after incubation with protocells bearing the indicated ratios of
EFNB1: EFNB2 at 37uC. (No inhibition seen for experiments at 4uC) b: Binding of soluble HeV G to protocells at 4uC. c: Binding of soluble HeV G to
protocells at 37uC. In panel a, the cells that have been infected are fluorescent and are shown in the top sections; in panels b and c, the protocells
binding soluble HeV G are fluorescent, and are shown in the top sections. HeV G binding is equivalent at 37uC and at 4uC and scales with EFNB2
concentration.
doi:10.1371/journal.pone.0016874.g006
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repeated experiments (use of fluorescent antibodies, SEM
examination and gel electrophoresis looking for viral proteins)
which shows that inactivation is not related to simple G binding;
the inactivation mechanism requires a temperature dependent
step. F activation is one of two critical steps in this process that is
temperature dependent. Second, while G-protein binding to the
EFNB2 receptor is equal at 4uC and 37uC, the membrane fluidity
at the lower temperature is reduced; reduced fluidity is the second
critical feature that is temperature dependent. Decreased fluidity
means an increased time for multiple copies of EFNB2 to
accumulate near a virus, which introduces the temporal
component to our hypothesis on the inactivation mechanism.
The experiments performed with mixtures of EFNB1 and EFNB2
also support this hypothesis – as EFNB2 is sterically blocked on the
membrane by EFNB1, the necessary signal can not be delivered in
a short enough time frame. There is a narrow window in time
during the virus interaction with the protocell for multiple EFNB2
receptors to engage the virus and cause F-protein triggering; if the
necessary signal is not satisfied, the virus appears to disengage
from the protocell and F-protein is not triggered.
There is urgent need for new, effective antiviral strategies for
paramyxoviruses, including the pediatric respiratory viruses para-
influenza and respiratory syncytial virus, as well as the emerging
henipaviruses and orthomyxoviruses. Acute respiratory infections
cause <20% of global mortality in children under five years of age,
and pediatric respiratory viruses in the paramyxovirus family
(parainfluenza virus, respiratory syncytial virus) account for a major
portion of this disease. This study presents a radical new antiviral
strategy, which could be applied to a wide range of viruses that
infect human beings via membrane fusion. If efficient receptor-
mimics can trigger and thus inactivate viral fusion machinery after
budding and release, but before contact with the next target cell,
then released virus could be rendered noninfectiousand viral spread
halted. This mechanism is of clinical relevance since therapy for
encephalitis, pneumonia and other diseases caused by paramyxo-
viruses and other enveloped viruses will often need to be effective
when used after the onset of infection.
The need for entirely new antiviral approaches is especially
urgent in light of recent evidence that the development of
resistance to antiviral drugs may be rapid. The global emergence
of influenza viruses resistant to oseltamivir has highlighted the
importance of developing new antiviral approaches that target
different portions of the viral infection machinery [21]. We suggest
that the design of this novel strategy in which the viral fusion
mechanism is ‘‘prematurely’’ triggered makes it unlikely to elicit
resistant viruses, since viruses that escape the effects of this strategy
will be overly handicapped. Mutant viruses with alterations in
their fusion proteins that could emerge under selective pressure
would have impaired fusion machinery triggering mechanisms,
and should be far less fit and transmissible than the parent viruses.
No virus whose fusion mechanism has triggered prematurely will
be able to infect, and no virus whose fusion machinery is not
triggerable will be able to infect. We propose that this new strategy
is thus highly unlikely to be rendered ineffective by viral resistance.
The approach we describe here may have wide potential for
antiviral applications, and the use of protocells may provide
significant advantages over available approaches.
Methods
Cells and viruses
293T (human kidney epithelial) and Vero (African green
monkey kidney cells) were grown in Dulbecco’s modified Eagle’s
medium (DMEM) (Mediatech; Cellgro) supplemented with 10%
fetal bovine serum and antibiotics in 5% CO2.
Plasmids, reagents and transient expression of G and F
HeV wild type G and F in pCAGGS were a gift from Lin-Fa
Wang. To generate the shortened cytoplasmic tail variant of HeV
G (HeV G-CT32 [22]), an internal primer containing an EcoR1
site and initiating at position 32 of the open reading frame was
used for nested PCR. The primer sequence was: 59 GGAATT-
CGGCACAATGGACATCAAG 39. To generate a soluble form
of HeV G, the extracytoplasmic domain of G was subcloned into
pSEC-tag (Invitrogen) [23]. Transfections were performed ac-
cording to the Lipofectamine 2000 reagent manufacturer’s
protocols (Invitrogen).
Rabbit polyclonal antibodies
Anti-HeV G and anti-HeV F polyclonal antibodies were raised
in rabbit by DNA immunization of HeV G or HeV F (Genovac).
Pseudovirus infection assay
The VSV-DG-RFP is a recombinant VSV derived from the
cDNA of VSV Indiana, in which the G gene is replaced with the
Ds-Red (RFP) gene. Pseudotypes with HeV F and G were
generated as described [7,23,24]. Briefly, 293T cells were
transfected with plasmids encoding either VSV-G, HeV-
GCT32/F, HeV-GCT32, or HeV-F. 24 hrs post-transfection,
the dishes were washed and infected (m.o.i. of 1) with VSV-DG-
RFP complemented with VSV G. Supernatant fluid containing
pseudovirus (HeV F/CT32-G or VSV-G) was collected 24 hrs
post-infection and stored at 280uC. For infection assays, HeV F/
CT32-G or VSV-G pseudotypes (controls) were used to infect
Vero cells. Various protocells or control agarose beads were added
at various times and concentrations as indicated in the figures.
RFP production at 36 h was analyzed by fluorescent microsco-
py[25] and flow cytometry.
Flow cytometry
Flow cytometry was performed on a BD FACS Vantage SE
with DiVa upgrade (BD Biosciences, San Jose, CA) equipped with
a Stabilite 2017 argon laser turned to 488 nm and a BeamLok
2060 argon-krypton laser turned to 568 nm, both from Spectra-
Physics (Mountain View, CA) at the Hospital for Special Surgery.
For RFP registration, the cells were excited with 568 nm and the
fluorescence of RFP emission was detected with a BP610/20 nm
filter.
Protocell Reagents
Nominal 10 mma n d3mm mesoporous silica microparticles
were purchased from GFS, each with nominal 10 nm internal
pore size. POPC and a nickel-chelating lipid, the nickel salt of
1,2-dioleoyl-sn-glycero-3-{[N(5-amino-1-carboxypentyl)iminodia-
cetic acid] (DOGS-NTA-Ni), were purchased from Avanti Polar
Lipids (Alabaster, AL) and dissolved in chloroform to form
solutions of 10 mg/mL and 1 mg/mL, respectively. Red
fluorescent dye, 1,2- dihexadecanoyl-sn-glycero-3- phosphoetha-
nolamine, triethylammonium salt (Texas-red DHPE), was
purchased from Invitrogen. His-tagged EFNB2 and EFNB1 was
purchased from Sigma-Aldrich and hydrated following the
manufacturers protocol. Alexa Fluor 488 donkey anti-rabbit
IgG was purchased from Sigma-Aldrich. Dilute phosphate
buffered saline (PBS) for washing and formation of lipid vesicles
was made by diluting 100 mL cell-culture grade 1X PBS with
400 mL of deionized (DI) water.
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Commercially purchased mesoporous silica microparticles
(GFS) were treated to form a hydrophilic surface before use.
The particles were stirred for 10 min at 85uC in 4% hydrogen
peroxide and 4% ammonium hydroxide, in water, followed by
repeated centrifugation and washing with DI water, stirring for
10 min at 85uC in 4% hydrogen peroxide and 0.4 mol/L
hydrochloric acid (HCl), in water, followed again by repeated
centrifugation and washing with DI water. The final particle
concentration was adjusted to <107 particles/mL.
Unilamellar lipid vesicles
POPC dissolved in chloroform (to 10 mg/mL) was mixed with
5% of 1 mg/mL 1,2-dioleoyl-sn-glycero-3-{[N(5-amino-1-carbox-
ypentyl)iminodiacetic acid] (DOGS-NTA-Ni, Avanti Polar Lipids,
Alabaster, AL) and 1% fluorescent Texas-red DHPE (in selected
experiments to confirm lipid presence, Invitrogen) in a glass vial
(dye was included in selected experiments to confirm lipid
presence). The solvent was evaporated using a nitrogen stream
until dry and the vial was kept under vacuum for 1 h to 2 h to
remove residual solvent. The lipid film was hydrated using
deionized (DI) water overnight at 4uC. The final lipid concentra-
tion was 2 mg/mL. The hydrated lipids were vortexed for several
minutes and were extruded using a mini-extruder (Avanti Polar
Lipids) with 0.1 mm polycarbonate membrane filters (Whatman,
Inc., Newton, MA). The lipid solution was passed through the
extruder at least 19 times and diluted with PBS to 1 mg/mL.
Lipid coating of protocells
A 1 mL aliquot of silica particle suspension was centrifuged, the
supernatant was removed, and 1 mL of the freshly prepared small
unilamellar vesicle solution was added and incubated with shaking
for 45 min to obtain silica particle supported lipid bilayers. The
final mixture was repeatedly centrifuged and washed in dilute PBS
to remove excess lipid.
Addition of receptor moieties to protocells
Lipid-coated particles were incubated with 50 mL of 100 mg/
mL of his-tagged EFNB2 (or EFNB1 for control samples, Sigma-
Aldrich) in PBS at room temperature for 30 min followed by
repeated centrifugation and washing in PBS to remove free
protein. The 3 mm diameter protocells have approximately 104
copies of the receptor protein on each particle after the completion
of synthesis.
Polymer beads
Highly cross-linked 6% agarose polymer microparticles (Che-
lating Sepharose Fast Flow, Amersham Biosciences) were used as
controls to produce particles with EFNB1 and EFNB2 attached to
the surface via a linker. The particles were charged with Ni2+ ions
and were used following the manufacturers protocols.
Supporting Information
Figure S1 Image of a typical gel electrophoresis exper-
iment to evaluate quantity of EFNB1 and EFNB2
incorporated into protocells. Left Panel: EFNB1 isolated
from 20 mL aliquot of EFNB1 bearing protocells compared to
molecular weight ladders and known quantities (1 mg, 0.2 mg, and
0.04 mg) of purified EFNB1. Right Panel: EFNB2 isolated from
20 mL aliquot of protocells compared to molecular weight ladders
and known quantities (1 mg, 0.2 mg, and 0.04 mg) of purified
EFNB2. In each case, the conclusion is that the 20 mL aliquot of
protocells contains approximately 0.2 mg of EFNB1 or EFNB2,
respectively.
(TIF)
Movie S1 Movie showing rotation of three dimensional
image based on three dimensional deconvolution of
fluorescent confocal z-stack images. The experiment
consisted of engineered HeLa cells expressing HeV G and F on
their membrane interacting with EFNB2 bearing protocells to
evaluate the bilayer formation on the protocells and protocell -
viral binding moiety interactions. The video shows well formed
lipid layers wrapped around each protocell and also shows the
protocells binding to cell membranes. In this reduced system, like
the experiments with soluble G binding to protocells and analyzed
with flow cytometry, simple binding does occur between EFNB2
bearing protocells and cells membranes’ expressing HeV G and F.
However, there is neither internalization of the protocells nor
fusion of the protocells and cell membranes. The HeLa cells were
expressing green fluorescent protein in the cytoplasm for imaging;
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